Maxim Group Lowers Biopharmx Corp (BPMX) Price Target to $1.50

Biopharmx Corp (AMEX:BPMX) had its price target reduced by research analysts at Maxim Group from $3.00 to $1.50 in a report released on Wednesday. The firm presently has a “buy” rating on the stock. Maxim Group’s target price would indicate a potential upside of 418.13% from the company’s previous close.

Separately, ValuEngine raised shares of Biopharmx Corp from a “strong sell” rating to a “sell” rating in a research report on Thursday, May 25th.

Biopharmx Corp (AMEX:BPMX) opened at 0.2895 on Wednesday. The stock’s market cap is $21.46 million. The company’s 50-day moving average price is $0.31 and its 200-day moving average price is $0.48. Biopharmx Corp has a one year low of $0.19 and a one year high of $0.90.

TRADEMARK VIOLATION WARNING: “Maxim Group Lowers Biopharmx Corp (BPMX) Price Target to $1.50” was first posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this news story can be read at

Biopharmx Corp Company Profile

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply